C9S

C9S (2 μM; 1 h) directly binds to purified metallothionein in in vitro protein-binding assays^[1].
C9S (10-40 μM; 24 h) is taken up by lung cancer cell line A549 in a concentration-dependent manner, and its uptake efficiency at concentrations of 10, 20 and 40 μM is significantly higher than that of the C9 probe after 24 h of incubation^[1].
C9S (5-80 μM; 24 h) does not significantly reduce the viability of lung cancer A549 cells at concentrations up to 40 μM after 24 h of incubation, but induces significant cytotoxicity at concentrations of 60 μM and 80 μM^[1].
Treatment of lung cancer A549 cells with C9S (40 μM; 24 h) downregulates 135 proteins, most of which contain potential arsenic-binding cysteine residues, and these proteins are enriched in key cellular metabolism and DNA processing pathways^[1].
Treatment of lung cancer cell line A549 with C9S (40 μM; 24 h) induces GSR degradation mediated by the ubiquitin-proteasome system and significantly downregulates the protein levels of EED and PLAA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.